Published in Clin Rheumatol on January 25, 2012
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol (2010) 1.91
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis (2010) 1.90
Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol (2002) 1.84
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess (2011) 1.43
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) (2006) 1.39
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis (2009) 1.05
ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther (2009) 0.93
Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol (2010) 0.84
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Rheumatoid arthritis association at 6q23. Nat Genet (2007) 6.71
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet (2008) 3.18
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol (2007) 3.09
The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) (2013) 3.07
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum (2003) 3.00
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet (2010) 2.56
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med (2007) 2.47
The 'short' history of regulatory B cells. Trends Immunol (2007) 2.38
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol (2011) 2.31
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet (2008) 2.08
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2009) 1.99
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum (2007) 1.98
Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum (2009) 1.95
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood (2011) 1.89
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med (2013) 1.89
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther (2010) 1.85
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) (2010) 1.83
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A (2008) 1.69
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol (2009) 1.67
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med (2010) 1.60
Informed conditioning on clinical covariates increases power in case-control association studies. PLoS Genet (2012) 1.57
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood (2002) 1.57
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum (2006) 1.56
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet (2009) 1.55
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) (2011) 1.55
Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation (2004) 1.53
Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol (2005) 1.52
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) (2009) 1.52
The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol (2009) 1.50
The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine (Phila Pa 1976) (2006) 1.46
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Identification of multiple, oxygen-stable HIF1 alpha isoforms, and augmented expression of adrenomedullin in rheumatoid arthritis. Clin Exp Rheumatol (2013) 1.40
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritis. Cutan Ocul Toxicol (2010) 1.39
Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet (2009) 1.37
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (2010) 1.36
Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 1.36
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2010) 1.34
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples. Ann Rheum Dis (2010) 1.31
Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol (2005) 1.29
Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum (2008) 1.28
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. BMJ (2002) 1.19
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples. Arthritis Rheum (2011) 1.18
Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis (2011) 1.17
Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol (2006) 1.16
Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol (2002) 1.16
Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum (2005) 1.16
Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol (2011) 1.14
Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13
Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett (2011) 1.09
HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis (2007) 1.08
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol (2006) 1.08
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Statins for atherosclerosis--as good as it gets? N Engl J Med (2005) 1.08
Modifiable risk factors for RA: prevention, better than cure? Rheumatology (Oxford) (2011) 1.08
Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum (2012) 1.07
Subclinical atherosclerosis in systemic lupus erythematosus. J Rheumatol (2004) 1.07
Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann Rheum Dis (2009) 1.07
PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann Rheum Dis (2009) 1.06
Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol (2008) 1.06
The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum (2006) 1.05
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol (2012) 1.04
The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum (2008) 1.04
Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis (2013) 1.03
The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol (2011) 1.03
Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Ann Rheum Dis (2010) 1.03
Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol (2004) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol (2007) 1.02
25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2011) 1.02
Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des (2011) 1.01
Gender-specific patterns of multiple concurrent sexual partnerships: a national cross sectional survey in Botswana. AIDS Care (2010) 1.01
Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol (2004) 1.00
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax (2012) 0.98
Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum (2013) 0.98
The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum (2013) 0.97
Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet (2013) 0.96